Latest Regulatory Decisions News

Page 6 of 6
The Takeovers Panel has declined to investigate applications challenging Pact Group Holdings’ proposed delisting, signaling regulatory acceptance of the move. The decision clarifies the Panel’s jurisdiction and leaves the delisting process on track.
Victor Sage
Victor Sage
22 May 2025
The Australian Competition and Consumer Commission (ACCC) has decided not to oppose Cleanaway Waste Management’s proposed acquisition of Citywide Waste, finding the deal unlikely to reduce competition in Melbourne’s putrescible waste services market.
Maxwell Dee
Maxwell Dee
15 May 2025
The Acting President of the Takeovers Panel has declined an interim order to postpone FBR Limited’s upcoming Extraordinary General Meeting, keeping the scheduled vote on track.
Sophie Babbage
Sophie Babbage
5 May 2025
Bounty Oil & Gas, through its joint venture operator Asset Energy, has initiated a judicial review against the refusal to vary and extend the PEP-11 offshore petroleum exploration permit. The legal challenge could reshape the future of this key Sydney Basin asset.
Victor Sage
Victor Sage
13 Feb 2025
The Takeovers Panel has declined to hear Global Lithium Resources’ review application concerning alleged undisclosed shareholder associations ahead of its upcoming AGM, citing procedural timing issues.
Maxwell Dee
Maxwell Dee
11 Feb 2025
The Takeovers Panel has declined to investigate Keybridge Capital’s applications alleging shareholder associations and takeover law breaches, clearing the way for an upcoming board replacement vote.
Claire Turing
Claire Turing
3 Feb 2025
The Takeovers Panel has declined to investigate Global Lithium Resources Limited's claims of undisclosed shareholder associations ahead of its AGM, citing untimeliness and lack of merit.
Maxwell Dee
Maxwell Dee
24 Jan 2025
Bubs Australia has reported a strong Q2 FY25 performance with a positive EBITDA turnaround and robust revenue growth, while advancing its critical FDA clinical trial in the US.
Eva Park
Eva Park
22 Jan 2025
Telix Pharmaceuticals has exceeded its full-year 2024 revenue guidance, driven by strong sales of its prostate cancer diagnostic Illuccix® and strategic pipeline advancements.
Ada Torres
Ada Torres
13 Jan 2025